Shots:
- The UK’s MHRA has approved Vimkunya for active immunization against CHIKV disease in individuals (≥12yrs.); launch expected in the summer of 2025. Application submitted to Health Canada, with potential approval anticipated in H1’26
- Approval was based on 2 P-III trials (n>3,500) that met their 1EP of rapid immune response within 1wk., with 97.8% of subjects aged 12–64yrs. & 87.3% aged >65yrs. developing neutralizing antibodies by day 21; seroresponse rates (2EP) were 46.6% (day 8) & 96.8% (day 15) for ages 12–64, & 82.3% (day 15) for those >65yrs. after vaccination
- Vimkunya is a single dose, prefilled adjuvanted VLP recombinant protein vaccine with an uncharacterized MoA
Ref: Globenewswire | Image: Bavarian Nordic
Related News:- Bavarian Nordic Reports the EC’s Approval of Vimkunya to Prevent Chikungunya
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
